Valneva
Specialty vaccine company focused on development, manufacturing and commercialization of prophylactic vaccines for infectious diseases. The company operates Vero-cell-based and recombinant-protein vaccine programs, has commercialized travel vaccines, and advances multiple candidates through clinical development in collaboration with external partners and public authorities.
Industries
Nr. of Employees
large (251-1000)
Patents
Method of producing pharmaceutical compositions comprising immunogenic chikungunya virus CHIKV-Δ5nsP3
US-12564625-B2
View DetailsSubunit vaccine for treatment or prevention of a respiratory tract infection
US-12162907-B2
View DetailsSubunit vaccine for treatment or prevention of a respiratory tract infection
US-12162909-B2
View Details
Method of producing pharmaceutical compositions comprising immunogenic chikungunya virus CHIKV-Δ5nsP3
US-12564625-B2
View DetailsSubunit vaccine for treatment or prevention of a respiratory tract infection
US-12162907-B2
View DetailsSubunit vaccine for treatment or prevention of a respiratory tract infection
US-12162909-B2
View DetailsProducts
Inactivated Vero-cell-derived Japanese encephalitis vaccine (commercial)
Licensed Vero-cell-derived inactivated vaccine indicated for prevention of Japanese encephalitis in travelers and at-risk populations.
Oral cholera/ETEC traveller vaccine (commercial)
Licensed oral vaccine indicated for prevention of cholera and, in some countries, prevention of diarrhea caused by enterotoxigenic E. coli (ETEC).
IXCHIQ®
Chikungunya vaccine approved in the United States, Canada and Europe.
Chikungunya vaccine
A single-shot prophylactic vaccine developed by Valneva for the prevention of chikungunya.
DUKORAL®
Cholera Vaccine.
VLA1553
A live-attenuated, single dose investigational vaccine candidate targeting the chikungunya virus.
Inactivated Vero-cell-derived Japanese encephalitis vaccine (commercial)
Licensed Vero-cell-derived inactivated vaccine indicated for prevention of Japanese encephalitis in travelers and at-risk populations.
Oral cholera/ETEC traveller vaccine (commercial)
Licensed oral vaccine indicated for prevention of cholera and, in some countries, prevention of diarrhea caused by enterotoxigenic E. coli (ETEC).
IXCHIQ®
Chikungunya vaccine approved in the United States, Canada and Europe.
Chikungunya vaccine
A single-shot prophylactic vaccine developed by Valneva for the prevention of chikungunya.
DUKORAL®
Cholera Vaccine.
VLA1553
A live-attenuated, single dose investigational vaccine candidate targeting the chikungunya virus.
Services
Collaborative partnerships with external pharmaceutical companies to co-develop late-stage vaccine candidates and support regulatory submissions.
Negotiation and execution of advance purchase and supply agreements with governments and international purchasers for vaccine doses.
Collaborative partnerships with external pharmaceutical companies to co-develop late-stage vaccine candidates and support regulatory submissions.
Negotiation and execution of advance purchase and supply agreements with governments and international purchasers for vaccine doses.
Expertise Areas
- Vaccine development (inactivated and recombinant protein)
- Clinical trial management and execution
- Vaccine manufacturing and scale-up
- Regulatory strategy and submissions (EMA/FDA)
Key Technologies
- Vero-cell vaccine manufacturing
- Inactivated whole-virus vaccine production
- Multivalent recombinant protein vaccine design
- Adjuvant formulation (alum + CpG-style adjuvants)
News & Updates
Webcast and analyst presentation for H1 2026 financial results.
Topline results from the Phase 3 VALOR trial showed more than 70% efficacy in preventing Lyme disease in individuals aged five and above; partner planning regulatory submissions.
Quarterly results reporting product sales, cash position and corporate cost-reduction program; update on partner regulatory filing plans for Lyme vaccine candidate.
Announcement of successful completion of a reserved equity offering to raise €84 million of proceeds (including contingent warrant proceeds).
Announcement that the European Commission approved an advance purchase agreement for up to 60 million doses of an inactivated COVID-19 vaccine produced on a Vero-cell platform.
Marketing Authorization Application validated by the European Medicines Agency for the multivalent recombinant OspA-based Lyme disease vaccine candidate.
Webcast and analyst presentation for H1 2026 financial results.
Topline results from the Phase 3 VALOR trial showed more than 70% efficacy in preventing Lyme disease in individuals aged five and above; partner planning regulatory submissions.
Quarterly results reporting product sales, cash position and corporate cost-reduction program; update on partner regulatory filing plans for Lyme vaccine candidate.
Announcement of successful completion of a reserved equity offering to raise €84 million of proceeds (including contingent warrant proceeds).
Announcement that the European Commission approved an advance purchase agreement for up to 60 million doses of an inactivated COVID-19 vaccine produced on a Vero-cell platform.
Marketing Authorization Application validated by the European Medicines Agency for the multivalent recombinant OspA-based Lyme disease vaccine candidate.